<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02585804</url>
  </required_header>
  <id_info>
    <org_study_id>REB# 14-8284-B</org_study_id>
    <nct_id>NCT02585804</nct_id>
  </id_info>
  <brief_title>Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects</brief_title>
  <acronym>TRANSLATE</acronym>
  <official_title>Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: &quot;The TRANSLATE Study&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Toronto General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Focal Segmental Glomerulosclerosis (FSGS) constitute an increasing proportion&#xD;
      of the total glomerulonephritis (GN) patient cohort in North America while FSGS is a risk&#xD;
      factor for end stage renal failure. Current non-immunological FSGS therapies include the use&#xD;
      of angiotensin converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB),&#xD;
      to reduce intraglomerular hypertension. Unfortunately, these agents lead to incomplete renal&#xD;
      protection. The aim of the current study is to determine whether the addition of novel sodium&#xD;
      glucose cotransport-2 inhibitors (SGLT2i) to standard of care leads to reduced&#xD;
      intraglomerular pressure and suppression of proteinuria. We hypothesize that combination&#xD;
      therapy of SGLT2i drugs and conventional RAASi results in additive renal protective effects&#xD;
      in FSGS patients. A further goal is to examine mechanisms of SGLT2 inhibition by measuring&#xD;
      renal hemodynamic function and sodium handling. Kidney function will be assessed in FSGS&#xD;
      patients before and after an 8 week treatment with SGLT2i dapagliflozin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      FSGS and diabetic nephropathy may have common pathogenic mechanisms, that are mediated by&#xD;
      intraglomerular hypertension, leading to hyperfiltration and proteinuria. Given that SGLT2i&#xD;
      corrects early hemodynamic abnormalities in patients with diabetes, our aim is to determine&#xD;
      if a similar benefit may extend to patients with FSGS. Based on previous experimental and&#xD;
      clinical data, we hypothesize that SGLT2i will improve renal hemodynamic abnormalities&#xD;
      characteristic of FSGS that promote renal injury and proteinuria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">April 24, 2017</completion_date>
  <primary_completion_date type="Actual">April 24, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in Glomerular Filtration Rate (GFR) After an 8 week treatment with dapagliflozin</measure>
    <time_frame>Before and after an 8 week treatment with dapagliflozin</time_frame>
    <description>Glomerular Filtration Rate (GFR, based on plasma inulin clearance) will be measured at baseline and after 8 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in Effective Renal Plasma Flow (ERPF) After an 8 week treatment with dapagliflozin</measure>
    <time_frame>Before and after an 8 week treatment with dapagliflozin</time_frame>
    <description>Effective Renal Plasma Flow (ERPF, based on paraaminohippurate plasma clearance) will be measured at baseline and after 8 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in Blood Pressure After an 8 week treatment with dapagliflozin</measure>
    <time_frame>Before and after 8 weeks of treatment with dapagliflozin</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in albuminuria after 8 weeks of treatment with dapagliflozin</measure>
    <time_frame>Before and after 8 weeks of treatment with dapagliflozin</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in urinary vasoactive mediators after 8 weeks of treatment with dapagliflozin</measure>
    <time_frame>Before and after 8 weeks of treatment with dapagliflozin</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Focal Segmental Glomerulosclerosis</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin (trade name Farxiga®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet, 10mg, PO, 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Oral tablet, 10mg, PO, 8 weeks</description>
    <arm_group_label>Dapagliflozin (trade name Farxiga®)</arm_group_label>
    <other_name>Trade name Farxiga®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects diagnosed with FSGS ≥1 month prior to informed consent&#xD;
&#xD;
          -  eGFR≥45 ml/min/1.73m2&#xD;
&#xD;
          -  Age 18 years or greater&#xD;
&#xD;
          -  No history of diabetes&#xD;
&#xD;
          -  Body Mass Index (BMI) 18.5 - 45.0 kg/ m2&#xD;
&#xD;
          -  Blood pressure ≥ 100/60 at screening&#xD;
&#xD;
          -  Stable therapy with either an ACEi or angiotensin II receptor blocker or direct renin&#xD;
             inhibitor for &gt; 1 month&#xD;
&#xD;
          -  &gt;30 mg/day and &lt;6 g/day of proteinuria unless the patient is not a candidate for&#xD;
             immunosuppressive therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Leukocyte and/or nitrite positive urinalysis that is untreated;&#xD;
&#xD;
          -  History of organ transplantation, cancer, liver disease;&#xD;
&#xD;
          -  Bariatric surgery or other gastrointestinal surgeries that induce chronic&#xD;
             malabsorption within the past two years;&#xD;
&#xD;
          -  Current treatment with systemic corticosteroids, calcineurin inhibitors, or other&#xD;
             immunosuppressant medications;&#xD;
&#xD;
          -  Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells;&#xD;
&#xD;
          -  Pre-menopausal women who are nursing, pregnant, or of child-bearing potential and not&#xD;
             practising an acceptable method of birth control;&#xD;
&#xD;
          -  Participation in another therapeutic trial with an investigational drug within 30 days&#xD;
             prior to informed consent;&#xD;
&#xD;
          -  Alcohol or drug abuse within three months prior to informed consent that would&#xD;
             interfere with trial participation or any ongoing clinical condition that would&#xD;
             jeopardize subject safety or study compliance based on investigator judgement;&#xD;
&#xD;
          -  Liver disease, defined by serum levels of alanine transaminase, aspartate&#xD;
             transaminase, or alkaline phosphatase &gt;3 x upper limit of normal as determined during&#xD;
             screening;&#xD;
&#xD;
          -  Cardiac, lung or peripheral vascular disease or stroke;&#xD;
&#xD;
          -  Pancreas, pancreatic islet cells or renal transplant recipient;&#xD;
&#xD;
          -  Medical history of cancer or treatment for cancer in the last five years prior to&#xD;
             screening;&#xD;
&#xD;
          -  History of allergy or angioedema with RAAS inhibitor exposure;&#xD;
&#xD;
          -  Kidney disease due primarily to another condition aside from FSGS;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Renal Physiology Laboratory, University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>October 22, 2015</study_first_submitted>
  <study_first_submitted_qc>October 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2015</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>David Z.I. Cherney</investigator_full_name>
    <investigator_title>Associate Professor of Medicine, Clinician Scientist</investigator_title>
  </responsible_party>
  <keyword>FSGS, SGLT2, chronic kidney disease, GFR, proteinuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuminuria</mesh_term>
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

